Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase II Trial of Erlotinib in Advanced Pancreatic Cancer

This study has been completed.
Sponsor:
Collaborator:
OSI Pharmaceuticals
Information provided by (Responsible Party):
University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT00497224
First received: July 4, 2007
Last updated: July 8, 2013
Last verified: July 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
No publications provided by University Health Network, Toronto

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):